跳至主要内容
临床试验/KCT0005010
KCT0005010已完成未知

The Relationship between cardiovascular disease and Brachial-ankle Pulse Wave Velocity(baPWV) in Patients with Type 2 Diabetes (REBOUND study)

Pusan National University Hospital0 个研究点目标入组 2,333 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
2,333

研究概览

简要总结

We found that a high-baPWV can predict all-cause and cause-specific mortality in subjects with type 2 diabetes. Our study is the first using a long-term and large-scale prospective cohort to present the appropriate baPWV cutoff point for cause-specific mortality, and demonstrates the predictive role of baPWV for cancer prognosis independent of conventional risk factors in people with type 2 diabetes. The measurement of baPWV as a noninvasive tool for arterial stiffness is useful for assessing mortality risk and, furthermore, 1,900 cm/s may be considered the optimal value for mortality risk assessment in type 2 diabetic patients.

研究设计

研究类型
Observational Study

入排标准

年龄范围
30(Year) 至 o Limit(—)
性别
All

入选标准

  • The inclusion criteria for patients
  • (i) patients with type 2 diabetes who were 30 years of age or older
  • (ii) baseline baPWV measured

排除标准

  • (i) type 1 diabetes mellitus;
  • (ii) an ankle brachial index (ABI) of <0.9
  • (iii) severe symptoms and/or signs of Cardiovascular disease
  • (iv) hospitalization within the previous three months due to acute myocardial infarction, stroke, or heart failure;
  • (v) chronic kidney disease (serum creatinine levels >2.0 mg/dL)

研究者

相似试验

Unknown
不适用
Relationship Between Morbimortality and Basal Activated Clotting Time (ACT) in Patients Undergoing Vascular SurgeryArtery Disease, PeripheralAortic DiseasesCarotid Artery DiseasesOther Disease
NCT04703582Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau30
进行中(未招募)
1 期
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 16.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849
EUCTR2012-003946-34-CZVIVUS, Inc.16,000
进行中(未招募)
1 期
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 14.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849
EUCTR2012-003946-34-SKVIVUS, Inc.16,000
进行中(未招募)
不适用
A study to test whether VI-0521 or placebo (contains no active drug substance) reduce the chances of developing health problems related to the functioning of the heart and vascular system (blood vessels), such as heart attacks or strokes.Cardiovascular Disease in overweight and obese subjectsMedDRA version: 16.0Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849
EUCTR2012-003946-34-GBVIVUS, Inc.16,000
已完成
不适用
Association Between Cardiovascular Diseases and Mental IllnessCardiovascular DiseasesMental Disorder
NCT06239246Ningbo No. 1 Hospital400